Search
IGN301
go.drugbank.com/drugs/DB05117ExperimentalIGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. … Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … Taletrectinib is an orally available small molecule kinase inhibitor.
Estradiol dienanthate
go.drugbank.com/drugs/DB13955ApprovedVet approvedWithdrawnin various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain. … Estradiol dienanthate is not currently available in any commercially available products in Canada or the US.
ING-1
go.drugbank.com/drugs/DB05831InvestigationalIt is an attractive target for immunotherapy. … ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most
Piperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalEurartesim was first authorized for market by the European Medicines Agency in October 2011. … It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label].
Cefroxadine
go.drugbank.com/drugs/DB11367ApprovedWithdrawnIt was used in Italy but has since been withdrawn. … Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to [cefalexin] as well as its activity spectrum.
Pimecrolimus
go.drugbank.com/drugs/DB00337ApprovedInvestigationalPimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. … It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Bitolterol
go.drugbank.com/drugs/DB00901ApprovedWithdrawnBitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Quinine
go.drugbank.com/drugs/DB00468ApprovedInvestigationalAn alkaloid derived from the bark of the cinchona tree. … It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633.
XEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.